Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Surg Oncol. 2016 May 20;25(3):190–199. doi: 10.1016/j.suronc.2016.05.018

Fig. 2.

Fig. 2

Progression free survival and overall survival in patients with mismatch repair deficient (MSI-H) and mismatch repair proficient colorectal cancer. Kaplan-Meier curves demonstrate PFS (A) and OS (B) in patients with colorectal cancer treated with the anti-PD1 antibody pembrolizumab. Shown are patients with mismatch repair deficient (MSI-H) tumors compared to mismatch repair proficient tumors. (Figures used with permission from Le et al. NEJM 2015).